N/A N=94 Simultaneous TransPRK and Corneal Collagen Cross-Linking
Keratoconus
Primary: Change in LogMAR Corrected Distance Visual Acuity (CDVA) — -0.13; -0.05 LogMAR CDVA — p=0.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=7 Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Carcinoma, Renal Cell
Primary: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT) — 0 participants
Phase 3 N=52 Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)
Anesthesia, General
Primary: Mean Time From Start Administration of Sugammadex to Recovery of Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 — 1.45; 1.32 minutes
N/A N=35 Exploring the Efficacy of Combined Task-Specific and Cognitive Strategy Training in Subacute Stroke
Stroke
Primary: Change From Baseline in Performance Quality Rating Scale (PQRS) — 2.9; 1.8; 4.5; 1.5 units on a scale
Phase 4 N=130 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
Relapsing-remitting Multiple Sclerosis
Primary: Change in T Cells Status (Decrease or Increase) at Month 48 (FAS) — -23.7; -1.2; 22.2; -37.2 percentage of parent population — p=< 0.0001
N/A N=23 A Trial Comparing Approaches to Shared Decision Making Skills Training for Clinicians
Depression · Low Back Pain
Primary: Change in Braddock's Informed Decision Making Score — 2.00; 1.25; 1.00; 3.20 score on a scale
Phase 4 N=278 Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
Japanese Encephalitis
Primary: Number and Percentage of Subjects With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 14; 243; 233; 24 Participants
Phase 1 N=16 A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)
Asthma
Primary: Percent Change From Baseline in Percent (%) Eosinophils in Induced Sputum At 8 Hours Post Allergen — -10.6; -7.3; 11.6 Percent change — p=0.011
Phase 2 N=53 Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
N/A N=166 The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Chronic Urticaria
Primary: Cross-Cultural Validity of Thai-version CU-Q2oL — 43.71; 22.11; 9.41; 20.21 Percentage — p=<0.01
Phase 4 N=221 Fever After Simultaneous Versus Sequential Vaccination in Young Children
Fever After Vaccination · Fever · Febrile Seizure
Primary: Number of Participants With Fever Following Vaccination — 8; 10 Participants — p=0.7588
N/A N=103 Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccine in Bangladeshi Adults and Children
Diarrhea
Primary: Number and Percentage of Participants With Serious Adverse Events (SAEs) — 0; 0; 1; 0 Participants
Phase 3 N=149 A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) After 16 Weeks of Treatment in Rosiglitazone Group and Placebo Group — -0.62; 0.19 Percentage of Glycosylated…
N/A N=167 Study Comparing BoneMaster Hydroxyapatite Coating With Plasma-sprayed Hydroxyapatite Coating on Acetabular Cups
Arthropathy of Hip
Primary: Record and Measure Bone Density Using DEXA Scans at 24 Months. — -11.0; 5.7 Net average BMD %change from baseline — p=0.4570
Phase 1 N=48 TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants
Depressive Disorder
Primary: Part 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 41.7; 66.7; 66.7; 50.0 percentage of participants